Osseous metastases: Drugs that enhance bone integrity and prevent adverse skeletal events

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 5, 2009, Pages 723-726

  Heun, James M ^a   Jatoi, Aminah ^a,b  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

Adverse skeletal events; Bisphosphonates; Bone pain; Fracture; Osseous metastases; Rib

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTITUSSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DECONGESTIVE AGENT; DENOSUMAB; ETIDRONIC ACID; GOSERELIN; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; TILUDRONIC ACID; ZOLEDRONIC ACID;

BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG RESPONSE; FLU LIKE SYNDROME; FRACTURE; HUMAN; KIDNEY DISEASE; PROTEINURIA; QUALITY OF LIFE; REVIEW; RIB; RISK FACTOR; SCLERITIS; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67649591938     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902832684     Document Type: Review

References (24)

1. Coleman RE, Guise TA, Lipton A, et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 2008;14:6387-6395
2. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008;98:1736-1740 (Pubitemid 351748847)
3. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-1867 (Pubitemid 47557312)
4. Hultborn R, Gunderson S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999;19:3383-3392 (Pubitemid 30000192)
5. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-854 (Pubitemid 29109314)
6. Hortabagyi GN, Theriault RL, Lipton A, et al. Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038-2044
7. Brincker H, Westin J, Abildgaard N, et al. Danish-Swedish Co-operative Study Group. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double blind placebo-controlled trial. Br J Haematol 1998;101:280-286
8. Berenson JR, Lichtenstein A, Porter L, et al. Myeloma Aredia Study Group. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602 (Pubitemid 28135605)
9. Kohno N, Aogi K, Minami H, et al. Zoledronic acid reduces skeletal complications compared to placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-3321 (Pubitemid 46243475)
10. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind placebo-controlled trial. Cancer 2004;100:2613-2621 (Pubitemid 38715767)
11. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-882 (Pubitemid 38807610)
12. Small EJ, Smith MR, Seaman JJ, et al. Placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-4284
13. Hirsh V, Tchekmedyian NS, Rosen LS, et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004;6:170-174 (Pubitemid 39618641)
14. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-1405 (Pubitemid 37185286)
15. Diel IJ, Body JJ, Lichinitser MR, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:1704-1712 (Pubitemid 38902906)
16. Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008;34(Suppl 1):S19-24
17. Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrazole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12 [abstract LBA4]. J Clin Oncol 2008;26(Suppl)
18. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clinic Proc 2006;81:1047-1053 (Pubitemid 44175016)
19. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-2472
20. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057
21. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491 (Pubitemid 351229318)
22. Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327:1-176
23. Lipton A, et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007;12:1035-1043 (Pubitemid 350007015)
24. Lipton A, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-4437 (Pubitemid 350013849)